Arvid Soderhall
Chief Executive Officer Empros Pharma
Dr. Arvid Söderhäll is an accomplished life sciences executive and physical chemist who currently serves as Chief Executive Officer of Empros Pharma, where he leads the company’s strategic vision to develop innovative therapeutics. With a career spanning drug development, regulatory affairs, and technology commercialization, he brings unique interdisciplinary expertise to biotech leadership.
Beyond his role at Empros Pharma, Dr. Söderhäll actively contributes to shaping the life sciences industry landscape. He previously chaired the Working Group for Clinical Trials and Regulatory Issues at SwedenBIO and served on the Steering Committee of Nordic MedTest, demonstrating his commitment to advancing industry standards and collaborative innovation.
His professional journey includes senior positions at IVA as a Project Manager and at Sidec as an Application Scientist, where he developed valuable experience in translating scientific innovation into practical solutions. Dr. Söderhäll holds a PhD in Physical Chemistry from Stockholm University, combining rigorous scientific training with executive business acumen.
Seminars
Join this session to explore how obesity trials and treatment paradigms must evolve with GLP-1 agonists as the new backbone therapy. Experts will debate optimal approaches for testing combinations and sequencing therapies, addressing critical questions about trial design, phenotypic targeting, and weight rebound mitigation.
- Determining patient-centric cardiometabolic endpoints to extend beyond weight loss while satisfying payer demands
- Combining dual GLP-1 and myostatin inhibitors to reduce muscle mass loss for greater metabolic health and explore composite endpoints that reflect real-world patient priorities to lower trial dropout rates
- Exploring sequential therapy protocols to reduce GI side effects for improved long-term adherence
- Reducing weight cycling by shifting focus from acute weight loss to sustained metabolic outcomes
